CAR T-Cell Therapy

Welcome to the CAR T-Cell Therapy Resource Center! Take a look around and find current information, news, literature, and other resources from this area of oncology treatment. We hope this site is helpful to your practice. If you have any feedback or questions, please contact editor@advancedpractitioner.com

Kathryn Ciccolini, AGACNP-BC, DNP, MSN, OCN
CAR-T/BMT Clinical Program Manager
Bone Marrow and Stem Cell Transplantation Program
Mount Sinai Hospital

CAR T-Cell Therapy for Large B-Cell Lymphoma

SITC Clinical Practice Guideline on Immune Effector Cell-related Adverse Events

Practical Guidance for the Diagnosis and Management of Secondary Hypogammaglobulinemia: A Work Group Report of the AAAAI Primary Immunodeficiency and Altered Immune Response Committees

CAR T-Cell Therapy Resource Center

Interview With Linda Ramsdell, MSN, FNP-BC, OCN: Administering CAR T-Cell Therapy in the Outpatient Setting

CAR T-Cell Therapy for Large B-Cell Lymphoma

SITC Clinical Practice Guideline on Immune Effector Cell-related Adverse Events

Practical Guidance for the Diagnosis and Management of Secondary Hypogammaglobulinemia: A Work Group Report of the AAAAI Primary Immunodeficiency and Altered Immune Response Committees

ASH-ASTCT COVID-19 Vaccination for HCT and CAR T Cell Recipients: Frequently Asked Questions

ASTCT NucleusPlus: Insights on Emerging CAR-T Therapies

CRISPR Therapeutics Press Release

CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX130™ for the Treatment of Cutaneous T-Cell Lymphomas (CTCL)

Nature Medicine

Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus

JAMA Oncology

Assessment of Pretreatment and Posttreatment Evolution of Neurofilament Light Chain Levels in Patients Who Develop Immune Effector Cell–Associated Neurotoxicity Syndrome

Haematologica

ATRA works synergistically with the γ-secretase inhibitor crenigacestat to augment BCMA on multiple myeloma and the efficacy of BCMA-CAR T-cells

JAMA Network Open

Geographic and Racial Disparities in Access to Chimeric Antigen Receptor–T Cells and Bispecific Antibodies Trials for Multiple Myeloma

Frontiers in Immunology

Comparable outcomes in patients with B-cell acute lymphoblastic leukemia receiving haploidentical hematopoietic stem cell transplantation

Lancet Oncology

New CAR T-cell therapy for solid tumours

Blood Cancer Discovery

Changes in Bone Marrow Tumor and Immune Cells Correlate with Durability of Remissions Following BCMA CAR T Therapy in Myeloma.

Blood Advances

Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy.

Blood Advances

Higher doses of tisagenlecleucel associate with improved outcomes: a report from the pediatric real-world CAR consortium.

Identifying CRS in Patients Who Underwent CAR T-Cell Infusion

Cytopenias After CAR T-cell Therapy: Varying Predictive Markers, Duration

Fast Facts #12: BCMA Targets